Kamada Ltd Stock News

KMDA remains a buy as it delivers strong earnings growth, robust cash generation, and trades at a discount to healthcare peers with an attractive FCF yield. Q2 results confirm ongoing operating leverage, with each $1 in new sales producing $3-$5 in incremental operating profit and EBITDA margins above industry averages. Strategic growth pillars—organic expansion and infrastructure investment, i...

Kamada Ltd. (NASDAQ:KMDA ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Philip Sidoti - Sidoti & Company, LLC Brian Ritchie - Lifesci Advisors, LLC Operator Greetings, ...

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.

REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations an...

Start Time: 08:30 January 1, 0000 8:53 AM ET Kamada Ltd. (NASDAQ:KMDA ) Q1 2025 Earnings Conference Call May 14, 2025, 08:30 AM ET Company Participants Amir London - CEO Chaime Orlev - CFO Brian Ritchie - LifeSci Advisors Conference Call Participants Annabel Samimy - Stifel James Sidoti - Sidoti & Company Operator Greetings, and welcome to the Kamada First Quarter 2025 Earnings Conference Call.

REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months ended March 31, 2025.

REHOVOT, Israel and HOBOKEN, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a third plasma collection cente...

Kamada Ltd. (NASDAQ:KMDA ) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ET Company Participants Brian Ritchie – LifeSci Advisors Amir London – Chief Executive Officer Chaime Orlev – Chief Financial Officer Conference Call Participants Annabel Samimy – Stifel Anthony Petrone – Mizuho Group James Sidoti – Sidoti & Co. Operator Greetings, and welcome to the Kamada Fourth Quarter and Full...